Rocket Pharmaceuticals, Inc. (NASDAQ:  RCKT) Securities Fraud Class Action

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Securities Fraud Class Action

Class Periodbetween February 27, 2025, and May 26, 2025
COMPANY       Rocket Pharmaceuticals, Inc.
COURT United States District Court for the District of New Jersey
CASE NUMBER 3:25-cv-10049
JUDGE The Honorable Zahid Nisar Quraishi
CLASS PERIOD  February 27, 2025, through May 26, 2025
SECURITY TYPE  Securities

LEAD PLAINTIFF DEADLINE IS AUGUST 11, 2025.

If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at [email protected].

Case Background:
A class action lawsuit was filed on behalf of those who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket”) (NASDAQ: RCKT) securities between February 27, 2025, and May 26, 2025, inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects.  Specifically, Defendants misrepresented and/or failed to disclose that: (1)  Rocket amended the protocol for the Phase 2 Study by introducing a novel immunomodulatory agent, a C3 inhibitor, to the pretreatment regime; (2) after the unannounced amendment to the protocol, at least one patient enrolled in the Phase 2 Study suffered from a Serious Adverse Event and died; (3) in the wake of the patient death, enrollment in the Phase 2 Study was halted and the FDA placed the Phase 2 Study on hold; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
 

What is a Lead Plaintiff?

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case.  Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Complete this form with your transactions in Rocket Pharmaceuticals, Inc. securities between February 27, 2025, and May 26, 2025.

Click Here to Print PDF of this Form

    Submit Your Information
    SUBMIT YOUR INFORMATION
    * Denotes required field
    Phone Country code
    Purchase Information
    Sales Information
    Did you purchase shares of Rocket Pharmaceuticals, Inc. prior to the Class Period?
    Are you a current or former employee of Rocket Pharmaceuticals, Inc.?
    The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. READ MORE
    I agree to the KTMC disclaimer
    I would like to receive new case alerts by email
    Scroll to Top